logo

Royality Med Pharmaceuticals Group

Royality Med's mission is to fast-track the early stage of drug discovery using our predictive models of the human brain for therapeutic success. Many neurodevelopmental diseases do not have treatments due to a lack of a-priori knowledge of the underlying biology. Royality Med's technology is able to model these diseases to help enable the discovery of new targets and drugs, de-risking the current failure-prone cumbersome approach.
For inquiries, please contact us at
E-mail: info@royalitymedgrp.com
mobile-logo
 

Scientific Advisors

Royality Med Pharmaceuticals Group (RMPG) boasts a network of top-tier scientific advisors in the field of neurodegenerative disorders. These experts provide invaluable support to Royality Med Pharmaceuticals Group (RMPG) with their specialized knowledge, offering critical input to both preclinical and clinical studies.

  1. Dr. Rino Rappuoli, MD

    Chief Medical Officer

    Dr. Rino Rappuoli is a prominent Italian immunologist and expert in vaccine development. He is known for his groundbreaking work on vaccines for infectious diseases, including the development of the first vaccine for meningitis B, which has saved countless lives worldwide. Dr. Rappuoli is the former Chief Scientist and Head of External R&D at GlaxoSmithKline (GSK) Vaccines and has been a pivotal figure in the global fight against infectious diseases. With more than 300 scientific publications and patents to his name, his contributions to immunology and vaccinology are widely recognized in the scientific community. Dr. Rappuoli is currently focusing on advancing new vaccine technologies, including those for emerging infectious diseases. He has received numerous awards for his pioneering work in the field of vaccinology and public health.



  2. Dr. Mario C. Mazzoleni, PhD

    Scientific Advisor

    Dr. Mario C. Mazzoleni is a Professor of Organic Chemistry at the University of Milan, Department of Pharmaceutical Sciences, Italy, since 2003. His research focuses on the discovery and development of bioactive compounds derived from plant natural products, with an emphasis on pharmacology, biochemistry, and medicinal chemistry. His work has led to the identification of several promising drug leads, including molecules for cancer and neurodegenerative diseases. He is the author of over 250 peer-reviewed articles and several patents related to natural product drug discovery. Dr. Mazzoleni serves as an Editorial Board member for the journal *Phytochemistry* and is also an active member of the European Society of Medicinal Plant Research. He has been recognized for his work in natural product chemistry with the prestigious *Italian Society of Organic Chemistry* Award in 2015.



  3. Dr. Vikas Bhardwaj, PhD

    Scientific Advisor

    Dr. Vikas Bhardwaj brings extensive experience from the global biotechnology and pharmaceutical industries, having worked with leading companies like GlaxoSmithKline and Roche as Senior Director of Drug Discovery. Dr. Bhardwaj and his team have uncovered key mechanisms of action of several natural compounds, advancing them as novel candidates for drug discovery. He was awarded the *Innovator of the Year* by Roche in 2015 for his pioneering contributions to drug discovery. Dr. Bhardwaj played a leading role in the research efforts that uncovered the mechanism of action of kinase inhibitors, which have now become a cornerstone in the treatment of various cancers. He holds a PhD in Molecular Pharmacology from the University of Delhi, India.



  4. Dr. Mario Fernandez, Ph.D.

    Scientific Advisor

    Dr. Mario Fernandez is a tenured Associate Professor in the Department of Neuroscience at the University of Barcelona, Spain. With over fifteen years of experience in neuropharmacology and molecular neurobiology, his research focuses on identifying new therapeutic targets for brain injury and neurodegenerative diseases. Currently, Dr. Fernandez's work aims at understanding the neuroinflammatory processes following traumatic brain injury and ischemic stroke, with an emphasis on developing therapies to protect the blood-brain barrier. His team uses cutting-edge techniques including molecular biology, genetic models, and imaging technologies to explore novel pathways for stroke recovery. Dr. Fernandez has contributed extensively to the field, authoring over 60 peer-reviewed publications, including several influential review articles and book chapters, and has received multiple research grants from the European Commission and Spanish research bodies.


I would like to learn about Royality Med’s Pharmaceuticals Group discoveries to treat genetic diseases.


YES, TELL ME MORE